Ranked #5,540 of 8,699 institutional investors
Foresite Capital Management V, LLC
West Hollywood, CA
$246M
US stock portfolio at live prices · today −$4.3M (−1.72%)
Live prices, last trade 10:32 AM ET
- Value at quarter end (Q3 2026)
- $289M
- Change from Q2 2026
- −$73.1M (−20.17%)
- Positions
- 8 · 1 new, 1 sold out
- Filed
- Nov 16, 2026
Not counted in the ranking: none$21.1M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesCGON 35.7%LTGO 18.6%IRON 11.4%ALMS 9.99%HIMS 5.52%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| CGON CG Oncology, Inc. | 1,079,050 | $88.1M | 35.7% | Unchanged |
| LTGO Latigo Biotherapeutics, Inc. | 3,562,984 | $45.8M | 18.6% | New |
| IRON Disc Medicine, Inc. | 374,069 | $28.2M | 11.4% | Unchanged |
| ALMS Alumis Inc. | 5,896,995 | $24.6M | 9.99% | Unchanged |
| HIMS Hims & Hers Health, Inc. | 883,751 | $13.6M | 5.52% | Added +20% |
| ODTX Odyssey Therapeutics, Inc. | 729,602 | $12.3M | 5.01% | Added +2% |
| EIKN Eikon Therapeutics, Inc. | 1,318,983 | $6.6M | 2.68% | Unchanged |
| NRIX Nurix Therapeutics, Inc. | 458,742 | $6.1M | 2.49% | Added +73% |
Sold out in Q3 2026
| Stock | Shares held at Q2 2026 | Worth today |
|---|---|---|
| LYEL Lyell Immunopharma, Inc. | 476,386 | $6.7M |